Information for the public Information for the public

FAQ

Home >> Information for the public >> FAQ

We provide information on your concerns regarding precision cancer treatment

logo img dot

For more detailed information,
please contact us at (kmaster@korea.ac.kr)
or +82-2-2286-1562/1564.

Q. Can I register now?

A. Yes, you can.
The program started in June 2017, and is currently open for inquiries.

Q. Are all cancer types included?

A. Yes.
All types of cancer are applicable, including rare ones, and genomic analysis will be performed. However, there may be limitations depending on ongoing studies and clinical trials available for the patient to enroll. The number of clinical trials will be continually expanded for the five years during which the project group is in operation, and thereafter as well.

Q. Will there really be a way to treat cancer once the genetic testing for cancer is performed?

A. You will be able to look for a treatment outside the current standard of care in cancer treatment. If you participate in the K-MASTER genetic testing for cancer, you can be provided with more accurate guidance on the current standard of care through biopsy as well as blood tests. Also, about 20% of patients can participate in a clinical trial for a new drug by identifying the right mutation for the patient.

Q. Is there any risk of personal information exposure during the cancer information integration process?

A. No, there is no risk.
We will build a trustworthy, safe system by establishing a precision medicine hospital information system at the national level; protecting personal information is our highest priority.

logo img dot

For more detailed information,
please contact us at (kmaster@korea.ac.kr)
or +82-2-2286-1562/1564.

Q. Can I register now?

A. Yes, you can.
The program started in June 2017, and is currently open for inquiries.

Q. Are all cancer types included?

A. Yes.
All types of cancer are applicable, including rare ones, and genomic analysis will be performed. However, there may be limitations depending on ongoing studies and clinical trials available for the patient to enroll. The number of clinical trials will be continually expanded for the five years during which the project group is in operation, and thereafter as well.

Q. Will there really be a way to treat cancer once the genetic testing for cancer is performed?

A. You will be able to look for a treatment outside the current standard of care in cancer treatment. If you participate in the K-MASTER genetic testing for cancer, you can be provided with more accurate guidance on the current standard of care through biopsy as well as blood tests. Also, about 20% of patients can participate in a clinical trial for a new drug by identifying the right mutation for the patient.

Q. Is there any risk of personal information exposure during the cancer information integration process?

A. No, there is no risk.
We will build a trustworthy, safe system by establishing a precision medicine hospital information system at the national level; protecting personal information is our highest priority.

logo img dot

For more detailed information,
please contact us at (kmaster@korea.ac.kr)
or +82-2-2286-1562/1564.

Q. Can I register now?

A. Yes, you can.
The program started in June 2017, and is currently open for inquiries.

Q. Are all cancer types included?

A. Yes.
All types of cancer are applicable, including rare ones, and genomic analysis will be performed. However, there may be limitations depending on ongoing studies and clinical trials available for the patient to enroll. The number of clinical trials will be continually expanded for the five years during which the project group is in operation, and thereafter as well.

Q. Will there really be a way to treat cancer once the genetic testing for cancer is performed?

A. You will be able to look for a treatment outside the current standard of care in cancer treatment. If you participate in the K-MASTER genetic testing for cancer, you can be provided with more accurate guidance on the current standard of care through biopsy as well as blood tests. Also, about 20% of patients can participate in a clinical trial for a new drug by identifying the right mutation for the patient.

Q. Is there any risk of personal information exposure during the cancer information integration process?

A. No, there is no risk.
We will build a trustworthy, safe system by establishing a precision medicine hospital information system at the national level; protecting personal information is our highest priority.

logo img dot

For more detailed information,
please contact us at (kmaster@korea.ac.kr)
or +82-2-2286-1562/1564.

Q. Can I register now?

A. Yes, you can.
The program started in June 2017, and is currently open for inquiries.

Q. Are all cancer types included?

A. Yes.
All types of cancer are applicable, including rare ones, and genomic analysis will be performed. However, there may be limitations depending on ongoing studies and clinical trials available for the patient to enroll. The number of clinical trials will be continually expanded for the five years during which the project group is in operation, and thereafter as well.

Q. Will there really be a way to treat cancer once the genetic testing for cancer is performed?

A. You will be able to look for a treatment outside the current standard of care in cancer treatment. If you participate in the K-MASTER genetic testing for cancer, you can be provided with more accurate guidance on the current standard of care through biopsy as well as blood tests. Also, about 20% of patients can participate in a clinical trial for a new drug by identifying the right mutation for the patient.

Q. Is there any risk of personal information exposure during the cancer information integration process?

A. No, there is no risk.
We will build a trustworthy, safe system by establishing a precision medicine hospital information system at the national level; protecting personal information is our highest priority.